Bracco International Bv

Bracco Suisse Sa

Bracco Imaging S.p.a.

Dyax Corporation

Bracco Research, USA

E. R. Squibb Sons, Inc.

Bracco S.p.a.

Kondareddiar Ramalingam

Karen E Linder

Adrian D Nunn

Edmund R Marinelli

Rolf E Swenson

Palaniappa Nanjappan

Natarajan Raju

Radhakrishna K Pillai

Mathew A Von Wronski

Michael F Tweedle

Bo Song

Ajay Shrivastava

Philippe Bussat

Hong Fan

Aaron Sato

Luciano Lattuada

Daniel T Dransfield

Sibylle Pochon

Christophe Arbogast

Feng Yan

Sharon Michele Walker

Ramachandran S Ranganathan

David P Nowotnik

Enrico Cappelletti

John P Pirro

William L Rumsey

Richard J DiRocco

Thangavel Arunachalam

Paul W Wedeking

Sudha Khurana

Fulvio Uggeri

Silvio Aime

Pierfrancesco Morosini

Robert Charles Ladner

Michel Schneider

Daniel J Sexton

Ruth Wager

Matteo Galli

Ruth E Wager

Pier Lucio Anelli

Alessandro Maiocchi

Bernard Lamy

Mario Virtuani

Hong (Helen) Fan

Andrea Beltrami

Luisella Calabi

Maurizio Franzini

Edmund E Marinelli

Vito Lorusso

Sybille Pochon

Nataranjan Raju

Radhakrishua Pillai

Mary Ellen Maddalena

Linda Chaabane

Richard J Di Rocco

Aaron K Sato

The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a K&#x3c;1 &#x3bc;M), and dimer and multimeric constructs comprising these polypeptides.

KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

The present invention provides polypeptides, peptide dimers, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a K&#x3c;1 &#x3bc;M), and dimer and multimeric constructs comprising these polypeptides, particularly contrast agents. Also provided are methods for monitoring and evaluating the therapeutic effectiveness of treatment protocols for diseases associated with angiogenesis or endothelial cell hyperproliferation, such as cancer, using contrast agents of the invention.

The present invention relates to a novel class of diagnostically or therapeutically effective compounds comprising novel peptides able to bind fibrin, to a process for their preparation and to compositions thereof for use in therapy and diagnostics. The compounds of the invention bind, in particular, to fibrin present in the extracellular matrix (EC) of tumor or connective tissue of stroma thus acting as targeting moieties able to bring and successfully bound an active moiety linked thereto to fibrin depositions inside solid tumors.

Fibrin binding peptide conjugates for diagnostic and therapeutic applications

The invention provides compositions and methods for therapeutic and diagnostic applications.

Multivalent constructs for therapeutic and diagnostic applications

The present invention relates to a novel class of paramagnetic ion-based contrast agents of formula (I), wherein a chelating backbone moiety is highly functionalized by the presence of one or more polyhydroxylated chain, that show a pharmacokinetic profile analogous to that of the commonly used T1-general extravascular agents (NSA) but are further characterized by a higher relaxivity.

Contrast agents endowed with high relaxivity

New and improved compounds for use in diagnostic imaging or therapy having the formula M-N&#x2014;O&#x2014;P-G, wherein M is a metal chelator having the structure: wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N&#x2014;O&#x2014;P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

Gastrin releasing peptide compounds

Improved compounds for use in diagnostic imaging or therapy having the formula M-N-O-P-G, wherein M is an optical label or a metal chelator (in the form complexed with a metal radionuclide or not), N-O-P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound are further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

Novel methods of treating prostate tumors or of delaying the progression of prostate tumors are also provided, including, methods of treating bone or soft tissue metastases of prostate cancer methods for treating hormone sensitive and hormone refractory prostate cancer, methods for delaying the progression of hormone sensitive prostate cancer, for facilitating combination therapy in patients with hormone sensitive prostate cancer and for decreasing aberrant vascular permeability in patients with hormone sensitive prostate cancer, said methods comprising the step of administering to a subject a dose comprising an amount of radioactively labeled L70, N-[4-[[[[[4,7,10-Tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]acetyl]amino]benzoyl]-L-glutaminyl-L-tryptophyl-L-alanyl-L-valyl-glycyl-L-histidyl-L-leucyl-L-methioninamide. 

New targeting or therapeutic compounds which can be incorporated into a composition of gas-filled microvesicles. The invention further relates to gas-filled microvesicles for diagnostic and/or therapeutic use comprising said compounds and to their method of use. The new compounds are compounds of formula M-S-T, wherein: M represents a component capable of associating with an envelope of a gas-filled microvesicle; T represents a component comprising a targeting ligand or a therapeutic agent; and S represents a component comprising at least two bissulfone groups.

Targeting and therapeutic compounds and gas-filled microvesicles comprising said compounds

The present invention provides compounds for targeting endothelial cells, tumor cells or other cells that express the NP-1 receptor, compositions containing the same and methods for their use. Additionally, the present invention includes diagnostic, therapeutic and radiotherapeutic compositions useful for visualization, therapy or radiotherapy.

Compounds for targeting endothelial cells, compositions containing the same and methods for their use

Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy

Growing community of inventors

Dayton, NJ, United States of America

Kondareddiar Ramalingam